Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships with suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry.

The extensive range includes drugs such as but not limited to: